Stockpolly
Search
Delisting risk
NCEL · NASDAQ · Biotechnology

NewcelX (NCEL)

Develops stem-cell-derived islet and astrocyte therapies for diabetes and ALS.

$3.48
At close+0.19 (+5.78%)
Watchlist

In millions of USD, except per-share figures

In millionsQ2 FY20Jun 2020Q4 FY20Dec 2020Q2 FY21Jun 2021Q4 FY21Dec 2021Q2 FY22Jun 2022Q4 FY22Dec 2022Q2 FY23Jun 2023Q4 FY23Dec 2023Q2 FY24Jun 2024Q4 FY24Dec 2024Q2 FY25Jun 2025Q4 FY25Dec 2025
Cost of revenue000000000000
Gross profit000000000000
115797842224
Research & development002463400000
113333302121
Selling & marketing113333302000
General & administrative000000000121
Other expenses000000040003
Operating income−1−1−5−7−9−7−8−4−2−2−2−4
00000−1000209
Interest income000000000000
Interest expense0000000000—6
Other non-operating income000000000−10−3
Income before tax−1−2−5−7−9−8−8−5−20−24
Income tax expense000000000000
Net income from continuing operations−1−2−5−7−9−8−8−5−20−24
Other adjustments000000050000
Net income−1−2−5−7−9−8−80−20−24
EPS, basic−$1.10−$3.40−$4.20−$5.00−$5.40−$2.90−$2.00−$1.40−$1.94−$26.30−$10.50$1.29
EPS, diluted−$1.10−$3.40−$4.20−$5.00−$5.40−$2.90−$2.00−$1.40−$1.94−$9.90−$10.50$1.29
Weighted average shares, basic101123434333
Weighted average shares, diluted101123434333
EBITDA−1−1−5−7−9−7−8—−2−2−2−1
Depreciation & amortization0000000—0000
EBIT−1−1−5−7−9−7−8−4−2−2−2−1